N-acetyl-L-cysteineWhat was measured
Measured, with no finding
920 endpoints
Show what was measuredHide what was measured
contrast-induced nephropathy, Fisher's Combined Test
decreases, p = 0.005
The Fisher's Combined Test was significant at p < 0.005 in favor of N-acetylcysteine
PMID 15562929 · one of two readings recorded this
relative risk reduction in contrast-induced nephropathy
decreases
There was a 62% relative risk reduction in contrast-induced nephropathy with N-acetylcysteine using a fixed-effects model
PMID 15562929 · one of two readings recorded this
relative risk reduction in contrast-induced nephropathy
decreases
a 70% relative risk reduction using the random-effects model
PMID 15562929 · one of two readings recorded this
size of N-acetylcysteine effect on contrast-induced nephropathy
decreases
The size of the N-acetylcysteine effect was to reduce contrast-induced nephropathy by 20%
PMID 15562929 · one of two readings recorded this
unpublished null trials needed to overturn combined significance (Rosenthal method)
p = 0.005
we found that 27 unpublished trials showing no effects of N-acetylcysteine would exist to overturn the combined significance of p < 0.005 of the five trials in our meta-analysis
PMID 15562929 · one of two readings recorded this
development of contrast-induced nephropathy
decreases
The relative risk of developing contrast-induced nephropathy was 0.43 (95% CI, 0.24 to 0.75) in subjects randomized to N-acetylcysteine
PMID 15836554 · one of two readings recorded this
incidence of dialysis
The incidence of dialysis was rare (0.2%)
PMID 15836554 · one of two readings recorded this
mean change in creatinine
decreases
The difference in mean change in creatinine between the N-acetylcysteine-treated group and controls was -0.27 mg/dl (95% confidence interval [CI], -0.43 to -0.11)
PMID 15836554 · one of two readings recorded this
relative risk of developing contrast-induced nephropathy at 48 hours; mean change in creatinine, NAC versus controls
RR 0.43, 95% CI 0.24 to 0.75
Not recorded as a finding: this platform holds no node for the endpoint
The relative risk of developing contrast-induced nephropathy was 0.43 (95% CI, 0.24 to 0.75) in subjects randomized to N-acetylcysteine.
PMID 15836554 · one of two readings recorded this
average patient age of trials
p = 0.24
Patient-related | Age (years) | 68 ± 4 | 70 ± 3 | 0.24
PMID 18001477 · one of two readings recorded this
baseline creatinine of trial populations
p = 0.09
Baseline creatinine (mg/dl) | 1.6 ± 0.4 | 2.2 ± 0.6 | 0.09
PMID 18001477 · one of two readings recorded this
CIN rate in control subjects
increases, p = 0.03
control subjects experienced more CIN in cluster 2 compared with cluster 1 trials (31% ± 10% versus 12% ± 6%; p = 0.03)
PMID 18001477 · one of two readings recorded this
contrast-induced nephrotoxicity incidence as defined in each trial (serum creatinine rise), relative risk by cluster of trials; change in serum creatinine; dialysis
no effect, p = 0.28
Not recorded as a finding: this platform holds no node for the endpoint
Cluster 1 studies (2445 patients) showed no benefit from NAC administration to prevent CIN (RR = 0.87; 95% CI 0.68–1.12, p = 0.28).
PMID 18001477 · one of two readings recorded this
contrast volume of trial populations
p = 0.11
Contrast volume (ml) | 158 ± 61 | 122 ± 46 | 0.11
PMID 18001477 · one of two readings recorded this
correlation of CIN relative risk with dialysis relative risk
unclear, p = 0.038
is positively correlated with the RR of requiring dialysis post-contrast (r = 0.66; p = 0.038)
PMID 18001477 · one of two readings recorded this
creatinine decrease in NAC-treated patients of cluster 2 studies
decreases, p = 0.07
relatively large creatinine decreases in NAC-treated patients (p = 0.07; open boxes on the right-hand side)
PMID 18001477 · one of two readings recorded this
creatinine increase in control patients of cluster 2 studies
increases, p = 0.02
these four studies have relatively large creatinine increases in control patients (p = 0.02; open boxes on the left-hand side)
PMID 18001477 · one of two readings recorded this
diabetes prevalence of trial populations
p = 0.93
Diabetes mellitus (%) | 43 ± 13 | 45 ± 13 | 0.93
PMID 18001477 · one of two readings recorded this
dialysis after contrast, all 22 trials
no effect, p = 0.42
A total of 13 patients received dialysis post-contrast (control n = 5, NAC-treated n = 8; p = 0.42)
PMID 18001477 · one of two readings recorded this
dialysis after contrast, cluster 1
no effect, p = 0.26
cluster 1 (control n = 4, NAC-treated n = 8; p = 0.26)
PMID 18001477 · one of two readings recorded this
dialysis after contrast, cluster 2
no effect, p = 1
cluster 2 (control n = 1, NAC-treated n = 0; p = 1.0)
PMID 18001477 · one of two readings recorded this
dialysis after contrast, pooled risk ratio
no effect, p = 0.54
NAC treatment showed no evidence of being protective using the clinical endpoint of dialysis events (RR = 1.42; CI 0.46–4.39, p = 0.54)
PMID 18001477 · one of two readings recorded this
difference in treatment effect between cluster 1 and cluster 2
modulates, p = 0.0001
these two sets of trials were found to have significantly different treatment effects (p < 0.0001)
PMID 18001477 · one of two readings recorded this
female proportion of trial populations
p = 0.31
Female (%) | 31 ± 14 | 22 ± 9 | 0.31
PMID 18001477 · one of two readings recorded this
heterogeneity among 22 trials for contrast-induced nephrotoxicity (CIN)
unclear, p = 0.04, n = 2746
significant heterogeneity (I2 = 37%; p = 0.04)
PMID 18001477 · one of two readings recorded this
incidence of contrast-induced nephrotoxicity (CIN)
no effect, p = 0.28, n = 2445
Cluster 1 studies (2445 patients) showed no benefit from NAC administration to prevent CIN (RR = 0.87; 95% CI 0.68–1.12, p = 0.28)
PMID 18001477 · one of two readings recorded this
incidence of contrast-induced nephrotoxicity (CIN)
decreases, p = 0.0001, n = 301
Cluster 2 studies (301 patients) indicated a large benefit from NAC treatment (RR = 0.15; CI 0.07–0.33, p < 0.0001)
PMID 18001477 · one of two readings recorded this
incidence of contrast-induced nephrotoxicity (CIN)
no effect, p = 0.35, n = 3268
showed no benefit of NAC for preventing CIN (RR = 0.90; 95% CI 0.72–1.12, p = 0.35)
PMID 18001477 · one of two readings recorded this
Jadad score of trials
p = 0.24
Jadad score (1–5) | 2.9 ± 1.5 | 2.0 ± 1.4 | 0.24
PMID 18001477 · one of two readings recorded this
meta-regression of NAC efficacy on age
no effect, p = 0.56
Patient-related | Age (years) | -0.13 | 0.56
PMID 18001477 · one of two readings recorded this
meta-regression of NAC efficacy on baseline creatinine
no effect, p = 0.96
Baseline Creatinine (mg/dl) | -0.01 | 0.96
PMID 18001477 · one of two readings recorded this
meta-regression of NAC efficacy on CIN event rate in control group
no effect, p = 0.35
CIN event rate in control group (%) | 0.21 | 0.35
PMID 18001477 · one of two readings recorded this
meta-regression of NAC efficacy on contrast volume
no effect, p = 0.24
Contrast volume (ml) | -0.27 | 0.24
PMID 18001477 · one of two readings recorded this
meta-regression of NAC efficacy on diabetes prevalence
no effect, p = 0.31
Diabetes mellitus (%) | -0.23 | 0.31
PMID 18001477 · one of two readings recorded this
meta-regression of NAC efficacy on female proportion
no effect, p = 0.72
Female (%) | 0.1 | 0.72
PMID 18001477 · one of two readings recorded this
meta-regression of NAC efficacy on Jadad score
no effect, p = 0.75
Jadad score (1–5) | 0.07 | 0.75
PMID 18001477 · one of two readings recorded this
meta-regression of NAC efficacy on publication date
no effect, p = 0.1
Study-related | Publication date (months after first) | 0.36 | 0.1
PMID 18001477 · one of two readings recorded this
meta-regression of NAC efficacy on study size
no effect, p = 0.54
Study size (number of patients) | 0.14 | 0.54
PMID 18001477 · one of two readings recorded this
meta-regression of NAC efficacy on total NAC dose
no effect, p = 0.25
Total NAC dose (mg) | -0.26 | 0.25
PMID 18001477 · one of two readings recorded this
publication date of studies
p = 0.05
Study-related | Publication date (months after first) | 38 ± 8 | 22 ± 17 | 0.05
PMID 18001477 · one of two readings recorded this
study size of trials
p = 0.23
Study size (number of patients) | 136 ± 106 | 75 ± 35 | 0.23
PMID 18001477 · one of two readings recorded this
three study factors combined
p = 0.01
All three factors combined | 34 ± 13 | 50 ± 9 | 0.01
PMID 18001477 · one of two readings recorded this
acute renal injury after cardiac surgery, absolute serum creatinine rise above 0.5 mg/dL or relative rise above 25% within 5 days, pooled relative risk for perioperative NAC versus placebo
RR 0.91, 95% CI 0.79-1.06, p = 0.24
Not recorded as a finding: the paper never states the instrument the node requires
N-Acetylcysteine did not reduce ARI incidence [35% NAC vs. 37% placebo; relative risk (RR) 0.91, 95% CI 0.79-1.06, P = 0.24].
PMID 19282300 · one of two readings recorded this
acute renal injury (ARI) incidence
no effect, p = 0.24, n = 1163
N-Acetylcysteine did not reduce ARI incidence [35% NAC vs. 37% placebo; relative risk (RR) 0.91, 95% CI 0.79-1.06, P = 0.24]
PMID 19282300 · one of two readings recorded this
acute renal injury (ARI) incidence
unclear, p = 0.06
There was a trend towards reduced ARI incidence among patients with baseline chronic kidney disease assigned to intravenous NAC (RR = 0.80, 95% CI 0.64-1.01, P = 0.06)
PMID 19282300 · one of two readings recorded this
death
no effect
3% died (RR = 1.10, 95% CI 0.56-2.16)
PMID 19282300 · one of two readings recorded this
haemodialysis requirement
no effect
Overall, 3.3% of patients required haemodialysis (NAC vs. placebo; RR = 1.13, 95% CI 0.59-2.17)
PMID 19282300 · one of two readings recorded this
heterogeneity of POAF incidence across trials
no effect, p = 0.366
with little statistical heterogeneity between the trials (I2 = 8.3%, heterogeneity P = 0.366)
PMID 22364379 · one of two readings recorded this
hospital length of stay in days, pooled WMD
WMD -0.07, 95% CI -0.42 to 0.28, p = 0.703
Not recorded as a finding: one-sided negation ('did not significantly reduce'), not a two-sided null
The pooled analysis using a fixed-effects model showed that NAC supplementation did not significantly reduce LOS (WMD -0.07, 95% CI -0.42 to 0.28; P = 0.703; Figure 3), with no statistical heterogeneity between the trials (I2 = 0.0%, heterogeneity P = 0.922).
PMID 22364379 · one of two readings recorded this
hospital length of stay (LOS)
no effect, p = 0.703, n = 283
NAC supplementation did not significantly reduce LOS (WMD -0.07, 95% CI -0.42 to 0.28; P = 0.703; Figure 3)
PMID 22364379 · one of two readings recorded this
hospital length of stay, weighted mean difference, days
WMD -0.07, 95% CI -0.42 to 0.28, p = 0.703
Not recorded as a finding: one-sided negation (did not significantly reduce); no two-sided statement in the sentence
The pooled analysis using a fixed-effects model showed that NAC supplementation did not significantly reduce LOS (WMD -0.07, 95% CI -0.42 to 0.28; P = 0.703; Figure 3), with no statistical heterogeneity between the trials (I2 = 0.0%, heterogeneity P = 0.922).
PMID 22364379 · one of two readings recorded this
incidence of postoperative atrial fibrillation (POAF)
decreases, p = 0.021, n = 578
NAC supplementation significantly reduced the incidence of POAF (OR 0.62, 95% CI 0.41 to 0.93; P = 0.021; Figure 2)
PMID 22364379 · one of two readings recorded this
incidence of postoperative atrial fibrillation (POAF)
decreases, n = 578
Pooling all eight randomized trials, 28.4% (82 of 289) of patients given NAC and 36.0% (104 of 289) of controls developed POAF
PMID 22364379 · one of two readings recorded this
incidence of postoperative atrial fibrillation (POAF)
decreases, p = 0.005
The pooled results didn't significantly change when this trial was excluded (OR 0.52, 95% CI 0.33 to 0.82; P = 0.005)
PMID 22364379 · one of two readings recorded this
POAF events per trial
n = 100
El-Hamamsy et al. | CABG | RCT (prospective) | Placebo | Yes | 3 | 4/50 | 6/50 | 5.4 ± 2.3 | 5.3 ± 2.5
PMID 22364379 · one of two readings recorded this
POAF events per trial
n = 20
Eren et al. | CABG | RCT (prospective) | Placebo | Yes | 3 | 2/10 | 1/10 | NA | NA
PMID 22364379 · one of two readings recorded this
POAF events per trial
n = 60
Haase et al. # | CABG and/or valve | RCT | Placebo | Yes | 5 | 19/30 | 16/30 | 8(7-11) | 8(7-11)
PMID 22364379 · one of two readings recorded this
POAF events per trial
n = 48
Kim et al. | CABG | RCT | Placebo | Yes | 4 | 4/24 | 8/24 | 11.3 ± 6.3 | 10.5 ± 4.5
PMID 22364379 · one of two readings recorded this
POAF events per trial
n = 20
Orhan et al. | CABG | RCT | Routine protocol | No | 3 | 0/10 | 1/10 | 7.2 ± 0.42 | 7.3 ± 0.48
PMID 22364379 · one of two readings recorded this
POAF events per trial
n = 115
Ozaydin et al. | CABG and/or valve | RCT (prospective) | Placebo | Yes | 4 | 3/58 | 12/57 | 7.7 ± 3 | 7.9 ± 4.2
PMID 22364379 · one of two readings recorded this
POAF events per trial
n = 40
Peker et al. | CABG | RCT (prospective) | Placebo | Yes | 4 | 0/19 | 2/21 | NA | NA
PMID 22364379 · one of two readings recorded this
POAF events per trial
n = 175
Wijeysundera et al. | CABG and/or valve | RCT | Placebo | Yes | 5 | 50/88 | 58/87 | NA | NA
PMID 22364379 · one of two readings recorded this
publication bias for POAF odds ratio (Egger's test)
no effect, p = 0.275
Egger's test, P = 0.275; Begg's test, P = 0.536
PMID 22364379 · one of two readings recorded this
length of stay (hospital or ICU not specified), duration of mechanical ventilation, incidence of new organ failure
no effect
Not recorded as a finding: one sentence covers three endpoints with no estimates; length of stay does not say hospital or ICU so no node can be chosen; ventilation duration left unrecorded as the sentence carries no estimate
Neither did N-acetylcysteine show any significant effect on length of stay, duration of mechanical ventilation or incidence of new organ failure.
PMID 22972094 · one of two readings recorded this
mortality in adults with SIRS or sepsis given intravenous NAC versus placebo, pooled risk ratio
no effect, RR 1.06, 95% CI 0.79 to 1.42
Not recorded as a finding: the paper never states the instrument the node requires
Mortality was similar in the N-acetylcysteine group and the placebo group (RR 1.06, 95% CI 0.79 to 1.42; I(2) = 0%).
PMID 22972094 · one of two readings recorded this
Mortality
no effect, n = 2768
Mortality was similar in the N-acetylcysteine group and the placebo group (RR 1.06, 95% CI 0.79 to 1.42; I(2) = 0%)
PMID 22972094 · one of two readings recorded this
1-year mortality
no effect, p = 0.67
which was not significantly lower among NAC recipients (15.4% vs. 21.4%, NAC vs. control, respectively, P = 0.67)
PMID 23383076 · one of two readings recorded this
Contrast-induced nephropathy (CIN), pooled risk ratio
no effect, p = 0.06, n = 1914
The overall pooled risk ratio (RR) of CIN using a random-effects model was 0.68 (95% CI, 0.45–1.02, p = 0.06)
PMID 23383076 · one of two readings recorded this
Contrast-induced nephropathy (CIN), pooled risk ratio
no effect, p = 0.12
The summary risk ratio for CIN associated with the use of NAC was essentially unchanged at 0.72 (95% CI, 0.47–1.09, p = 0.12)
PMID 23383076 · one of two readings recorded this
Contrast-induced nephropathy (CIN), pooled risk ratio
decreases, p = 0.04
(RR = 0.59; 95% CI, 0.36–0.97, p = 0.04)
PMID 23383076 · one of two readings recorded this
Contrast-induced nephropathy (CIN), pooled risk ratio
no effect, p = 0.2
demonstrated no benefit for NAC with a summary risk ratio of 0.77 (95% CI, 0.50–1.15, p = 0.20)
PMID 23383076 · one of two readings recorded this
In-hospital mortality, pooled relative risk
no effect, p = 0.29
The pooled relative risk of in-hospital mortality with intravenous NAC in the four trials was 0.67 (95% CI, 0.32–1.40, P = 0.29)
PMID 23383076 · one of two readings recorded this
Incidence of CIN, average across studies
The incidence of CIN in the control group ranged from 5.9% to 23.8% with an average of 14.3%
PMID 23383076 · one of two readings recorded this
Incidence of CIN, average across studies
The incidence of CIN in the treatment group ranged from 2.5% to 16.0% with an average of 7.9%
PMID 23383076 · one of two readings recorded this
incidence of contrast-induced nephropathy, rise in serum creatinine of at least 0.5 mg/dL or 25% above baseline after contrast exposure, pooled risk ratio for intravenous NAC
RR 0.68, 95% CI 0.45-1.02, p = 0.06
Not recorded as a finding: this platform holds no node for the endpoint
The overall pooled risk ratio (RR) of CIN using a random-effects model was 0.68 (95% CI, 0.45–1.02, p = 0.06), indicating a nonsignificant trend towards benefit in patients who received NAC.
PMID 23383076 · one of two readings recorded this
Meta-regression of CIN relative risk on allocation concealment
no effect, p = 0.17
Allocation concealment † | 0.73 | −0.38 to 1.85 | 0.17
PMID 23383076 · one of two readings recorded this
Meta-regression of CIN relative risk on baseline creatinine
no effect, p = 0.16
Baseline Creatinine | −1.02 | −2.5 to 0.50 | 0.16
PMID 23383076 · one of two readings recorded this
Meta-regression of CIN relative risk on contrast volume
no effect, p = 0.92
Contrast volume | −0.08 | −1.91 to 1.75 | 0.92
PMID 23383076 · one of two readings recorded this
Meta-regression of CIN relative risk on diabetes mellitus
no effect, p = 0.83
Diabetes mellitus | −0.01 | −0.08 to 0.07 | 0.83
PMID 23383076 · one of two readings recorded this
Meta-regression of CIN relative risk on double-blinding
no effect, p = 0.17
Double-blinding † | 0.66 | −0.35 to 1.66 | 0.17
PMID 23383076 · one of two readings recorded this
Meta-regression of CIN relative risk on intention to treat analysis
no effect, p = 0.45
Intention to treat analysis † | −0.42 | −1.67 to 0.82 | 0.45
PMID 23383076 · one of two readings recorded this
Meta-regression of CIN relative risk on Jadad score
no effect, p = 0.59
Jadad score | 0.13 | −0.39 to 0.64 | 0.59
PMID 23383076 · one of two readings recorded this
Meta-regression of CIN relative risk on publication date
no effect, p = 0.8
Publication date | −0.02 | −0.18 to 0.15 | 0.80
PMID 23383076 · one of two readings recorded this
Meta-regression of CIN relative risk on study size
no effect, p = 0.08
Study size | 0.98 | −0.12 to 2.07 | 0.08
PMID 23383076 · one of two readings recorded this
Meta-regression of CIN relative risk on total NAC dose
no effect, p = 0.58
Total NAC dose | −0.04 | −0.20 to 0.12 | 0.58
PMID 23383076 · one of two readings recorded this
Renal failure requiring dialysis, pooled risk ratio
no effect, p = 0.72
The pooled risk ratio of renal failure requiring dialysis was 0.72 (95% CI, 0.34 to 4.75, P = 0.72)
PMID 23383076 · one of two readings recorded this
All-cause mortality
decreases, p = 0.03
Use of NAC was associated with a reduction in all-cause death (OR 0.40; 95% CI 0.17 to 0.93; P = 0.03
PMID 24739515 · one of two readings recorded this
all-cause mortality, pooled OR in cardiac surgery
decreases, OR 0.40; 95% CI 0.17 to 0.93, p = 0.03
Not recorded as a finding: all-cause-mortality node requires the follow-up horizon to be recorded and the paper states none for the pooled estimate
Use of NAC was associated with a reduction in all-cause death (OR 0.40; 95% CI 0.17 to 0.93; P = 0.03; I2 = 0%, Pheterogeneity =0.44; Figure 6).
PMID 24739515 · one of two readings recorded this
All-cause mortality, pooled proportion
decreases
Death occurred in 5 of 513 patients (0.9%) treated with NAC and in 16 of 513 patients (3.1%) treated with placebo
PMID 24739515 · one of two readings recorded this
Cerebrovascular events, pooled proportion
no effect
Cerebrovascular events occurred in 8 of 423 patients (1.9%) treated with NAC and in 5 of 424 patients (1.2%) treated with placebo
PMID 24739515 · one of two readings recorded this
Cerebrovascular events
no effect, p = 0.32
Prophylactic use of NAC failed to present a reduction in cerebrovascular accidents (OR 1.68; 95% CI 0.60 to 4.69; P = 0.32
PMID 24739515 · one of two readings recorded this
hospital length of stay, pooled WMD
WMD 0.09; 95% CI -0.13 to 0.31, p = 0.4
Not recorded as a finding: one-sided negation ('did not reduce'), not a two-sided null
The meta-analysis of the five studies using a fixed-effects model presented that NAC treatment did not reduce the length of hospital stay (WMD 0.09; 95% CI −0.13 to 0.31; P = 0.40; Figure 5).
PMID 24739515 · one of two readings recorded this
hospital length of stay, weighted mean difference, days
WMD 0.09; 95% CI -0.13 to 0.31, p = 0.4
Not recorded as a finding: one-sided negation (did not reduce); no two-sided statement in the sentence
The meta-analysis of the five studies using a fixed-effects model presented that NAC treatment did not reduce the length of hospital stay (WMD 0.09; 95% CI −0.13 to 0.31; P = 0.40; Figure 5).
PMID 24739515 · one of two readings recorded this
ICU length of stay, pooled WMD in hours
WMD 0.60; 95% CI -0.97 to 2.16, p = 0.45
Not recorded as a finding: one-sided negation ('not associated with a reduction'), not a two-sided null
Prophylactic NAC was not associated with a reduction in ICU length of stay (WMD 0.60; 95% CI −0.97 to 2.16; P = 0.45).
PMID 24739515 · one of two readings recorded this
ICU length of stay, weighted mean difference, hours
WMD 0.60; 95% CI -0.97 to 2.16, p = 0.45
Not recorded as a finding: one-sided negation (not associated with a reduction); no two-sided statement in the sentence
Prophylactic NAC was not associated with a reduction in ICU length of stay (WMD 0.60; 95% CI −0.97 to 2.16; P = 0.45).
PMID 24739515 · one of two readings recorded this
incidence of cerebrovascular events after cardiac surgery (nonfatal), odds ratio
OR 1.68; 95% CI 0.60 to 4.69, p = 0.32
Not recorded as a finding: no stroke-incidence node match on stated definition and one-sided negation (failed to present a reduction)
Prophylactic use of NAC failed to present a reduction in cerebrovascular accidents (OR 1.68; 95% CI 0.60 to 4.69; P = 0.32; I2 = 0%, Pheterogeneity =0.64).
PMID 24739515 · one of two readings recorded this
incidence of cerebrovascular events, pooled OR
OR 1.68; 95% CI 0.60 to 4.69, p = 0.32
Not recorded as a finding: no outcome node for cerebrovascular events (stroke-incidence node is a different adjudicated endpoint) and one-sided negation
Prophylactic use of NAC failed to present a reduction in cerebrovascular accidents (OR 1.68; 95% CI 0.60 to 4.69; P = 0.32; I2 = 0%, Pheterogeneity =0.64).
PMID 24739515 · one of two readings recorded this
Incidence of postoperative atrial fibrillation (POAF), pooled proportion
decreases
Pooling all ten RCTs, 20.5% (105 of 513) of patients given NAC and 28.8% (148/513) of controls developed POAF
PMID 24739515 · one of two readings recorded this
Incidence of postoperative atrial fibrillation (POAF)
decreases, p = 0.001, n = 1026
NAC reduced the incidence of POAF (OR 0.56, 95% CI 0.40 to 0.77; P < 0.001
PMID 24739515 · one of two readings recorded this
Incidence of postoperative atrial fibrillation (POAF)
decreases, p = 0.001
The meta-analysis of the remaining studies (OR 0.57, 95% CI 0.40 to 0.80; P = 0.001)
PMID 24739515 · one of two readings recorded this
Incidence of postoperative atrial fibrillation (POAF)
decreases, p = 0.001
A trial enrolled some patients with a history of AF, but the pooled results (OR 0.50; 95% CI 0.35 to 0.71; P < 0.001
PMID 24739515 · one of two readings recorded this
Incidence of postoperative atrial fibrillation (POAF)
decreases, p = 0.001
(OR 0.40; 95% CI 0.25 to 0.65; P < 0.001; I2 = 22%, Pheterogeneity =0.28; Figure 3)
PMID 24739515 · one of two readings recorded this
Incidence of postoperative atrial fibrillation (POAF)
no effect, p = 0.09
it failed to reduce the incidence of POAF with a short-term NAC (within 24 h after surgery) supplementation (OR 0.64; 95% CI 0.39 to 1.06; P = 0.09
PMID 24739515 · one of two readings recorded this
Length of hospital stay
no effect, p = 0.4
NAC treatment did not reduce the length of hospital stay (WMD 0.09; 95% CI −0.13 to 0.31; P = 0.40
PMID 24739515 · one of two readings recorded this
Length of ICU stay
no effect, p = 0.45
Prophylactic NAC was not associated with a reduction in ICU length of stay (WMD 0.60; 95% CI −0.97 to 2.16; P = 0.45)
PMID 24739515 · one of two readings recorded this
Adverse events (risk of side-effects)
no effect, p = 0.4
NAC did not significantly increase the risk of side-effects (relative risk 0.94, 95% CI 0.88–0.99; p=0.40)
PMID 26324807 · one of two readings recorded this
Adverse events (risk of side-effects)
no effect, p = 0.58
high doses relative risk 1.11, 95% CI 0.89–1.39; p=0.58
PMID 26324807 · one of two readings recorded this
Adverse events (risk of side-effects)
no effect, p = 0.4
low doses relative risk 0.93, 95% CI 0.89–0.97; p=0.40
PMID 26324807 · one of two readings recorded this
Adverse events (risk of side-effects)
no effect, p = 0.21
Jadad score ≤3, five studies: treated n=521, placebo n=513; relative risk 0.85, 95% CI 0.47–1.53; p=0.21
PMID 26324807 · one of two readings recorded this
Frequency of COPD exacerbations
decreases, p = 0.01, n = 4155
significantly reduced the frequency of exacerbations (relative risk 0.75, 95% CI 0.66–0.84; p<0.01)
PMID 26324807 · one of two readings recorded this
Frequency of COPD exacerbations
decreases, p = 0.03
treated n=635, placebo or controls n=1362) and showed a significant reduction of COPD exacerbation rate (relative risk 0.65, 95% CI 0.49–0.88; p=0.03)
PMID 26324807 · one of two readings recorded this
Frequency of COPD exacerbations
decreases, p = 0.04
two studies: treated n=534, placebo n=538; relative risk 0.75, 95% CI 0.68–0.82; p=0.04
PMID 26324807 · one of two readings recorded this
Frequency of COPD exacerbations
decreases, p = 0.01
treated n=1298, placebo or controls n=1614) significantly protected against COPD exacerbations (relative risk 0.76, 95% CI 0.65–0.89; p<0.01)
PMID 26324807 · one of two readings recorded this
Frequency of COPD exacerbations
decreases, p = 0.01
relative risk 0.90, 95% CI 0.84–0.96; p<0.01) in the analysis of those RCTs where COPD was diagnosed using PFT (patients from five studies: treated n=444, placebo n=433)
PMID 26324807 · one of two readings recorded this
Frequency of COPD exacerbations
decreases, p = 0.01
seven studies: treated n=978, placebo n=971; relative risk 0.78, 95% CI 0.65–0.93; p<0.01
PMID 26324807 · one of two readings recorded this
Frequency of COPD exacerbations
decreases, p = 0.01
seven studies: treated n=957, placebo n=955; relative risk 0.85, 95% CI 0.74–0.98; p<0.01
PMID 26324807 · one of two readings recorded this
Frequency of COPD exacerbations
decreases, p = 0.07
six studies: treated n=986, placebo n=1267; relative risk 0.64, 95% CI 0.56–0.74; p=0.07
PMID 26324807 · one of two readings recorded this
Serious adverse events
no effect, p = 0.81
eight studies: treated n=1272, placebo n=1267; relative risk 0.95 95% CI 0.67–1.34; p=0.81
PMID 26324807 · one of two readings recorded this
change in 6 minute walk test distance (6MWT), pooled SMD, idiopathic pulmonary fibrosis; also change in %VC, FVC, %DLco, adverse events, death
SMD = 0.25, 95% CI: 0.02-0.48, p = 0.04
Not recorded as a finding: another reason, stated per paper
The decline in 6MWT was significantly less in the N-acetylcysteine group (SMD = 0.25, 95% CI: 0.02–0.48; P = 0.04).
PMID 27175674 · one of two readings recorded this
Change in 6-minute walk test distance (Δ6MWT)
increases, p = 0.04
Fixed model: 148 of acetylcysteine, 146 of control, SMD = 0.25, 95% CI 0.02–0.48, P = 0.04
PMID 27175674 · one of two readings recorded this
Change in forced vital capacity (ΔFVC)
no effect, p = 0.52
Fixed model: 191 of acetylcysteine, 188 of control, SMD = 0.07, 95% CI −0.13–0.27, P = 0.52
PMID 27175674 · one of two readings recorded this
Change in percentage of predicted carbon monoxide diffusing capacity (Δ%DLco)
no effect, p = 0.18
Fixed model: 242 of acetylcysteine, 232 of control, SMD = 0.12, 95% CI −0.06–0.30, P = 0.18
PMID 27175674 · one of two readings recorded this
change in percentage of predicted vital capacity, change in forced vital capacity, change in percentage of predicted DLco, change in 6-minute walk test distance (SMD), pooled in IPF
decreases, SMD = 0.37, 95% CI 0.13 to -0.62, p = 0.003
Not recorded as a finding: this platform holds no node for the endpoint
The decrease in %VC was significantly less in the N-acetylcysteine group than in the control group (SMD = 0.37, 95% CI: 0.13 to −0.62; P = 0.003).
PMID 27175674 · one of two readings recorded this
Change in percentage of predicted vital capacity (Δ%VC)
increases, p = 0.003
Fixed model: 130 of acetylcysteine, 129 of control, SMD = 0.37, 95% CI 0.13–0.62, P = 0.003
PMID 27175674 · one of two readings recorded this
Rate of adverse events
no effect, p = 0.35
Random model: 177 of acetylcysteine, 177 of control, OR = 4.5, 95% CI 0.19–106.41, P = 0.35
PMID 27175674 · one of two readings recorded this
Rate of death
no effect, p = 0.28
Random model: 286 of acetylcysteine, 278 of control, OR = 1.79, 95% CI 0.63–5.12, P = 0.28
PMID 27175674 · one of two readings recorded this
Craving symptoms in substance abuse disorders
decreases, n = 245
The result was derived from pooled analysis of 7 randomised control trials with heterogeneous methodology and a small sample size of 245
PMID 30426004 · one of two readings recorded this
Depressive symptoms in unipolar depression
decreases, n = 252
In this double-blind, placebo-controlled trials with 252 participants, N-acetylcysteine treatment of 2000 mg/day significantly improved depressive symptoms over the 16 weeks trial period compared to placebo
PMID 30426004 · one of two readings recorded this
Severity of obsessive-compulsive symptoms
no effect, n = 40
Costa et al. did not find any significant benefit of N-acetylcysteine in reducing the severity of obsessive-compulsive symptoms among 40 treatment-resistant adults in a 16-week double-blind, placebo-controlled study of N-acetylcysteine (3,000 mg/day)
PMID 30426004 · one of two readings recorded this
Total and negative symptoms of schizophrenia
decreases, n = 46
Those treated with N-acetylcysteine (1000 mg/day in the first week increasing to 2000 mg/day for 7 weeks) achieved statistically significant improvements in the total and negative symptoms of schizophrenia compared to those on placebo, over the 8-week period
PMID 30426004 · one of two readings recorded this
allergic adverse events
no effect, n = 336
or allergic adverse events (2% versus 0%, RR 2.98, 95% CI 0.32 to 27.74; participants = 336; studies = five; very low-certainty evidence)
PMID 30746681 · one of two readings recorded this
gastrointestinal adverse events
no effect, n = 336
whether NAC is associated with a higher risk of gastrointestinal adverse events compared to control (23.9% versus 18.9%, RR 1.25, 95% CI 0.85 to 1.85; participants = 336; studies = five; very low-certaintyevidence)
PMID 30746681 · one of two readings recorded this
H pylori eradication rate
no effect, n = 559
(38.8% versus 49.1%, risk ratio (RR) 0.74, 95% confidence interval (CI) 0.51 to 1.08; participants = 559; studies = eight; very low-certainty evidence)
PMID 30746681 · one of two readings recorded this
H pylori eradication rate
increases, n = 397
the addition of NAC may improve eradication rates compared to control (27.2% versus 37.6%, RR 0.71, 95% CI 0.53 to 0.94; participants = 397; published studies = five)
PMID 30746681 · one of two readings recorded this
Helicobacter pylori eradication rate, NAC added to antibiotic regimen versus the same regimen with placebo or no NAC, pooled risk ratio
RR 0.74, 95% CI 0.51 to 1.08, n = 559
Not recorded as a finding: a direction is stated and the estimate does not support it
We are uncertain whether the addition of NAC to antibiotics improves H pylori eradication rates, compared with the addition of placebo or no NAC (38.8% versus 49.1%, risk ratio (RR) 0.74, 95% confidence interval (CI) 0.51 to 1.08; participants = 559; studies = eight; very low-certainty evidence).
PMID 30746681 · one of two readings recorded this
Helicobacter pylori eradication rate with NAC added to antibiotics versus antibiotics with placebo or no NAC, eight randomised trials
RR 0.74, 95% CI 0.51 to 1.08 (38.8% versus 49.1%), n = 559
Not recorded as a finding: the direction is carried only as a signed number
We are uncertain whether the addition of NAC to antibiotics improves H pylori eradication rates, compared with the addition of placebo or no NAC (38.8% versus 49.1%, risk ratio (RR) 0.74, 95% confidence interval (CI) 0.51 to 1.08; participants = 559; studies = eight; very low-certainty evidence).
PMID 30746681 · one of two readings recorded this
adverse events event counts (GRADE profile)
no effect
4 | Randomized trials | Not serious | Not serious | Not serious | Not serious | None | 7/237 (3.0%) | 15/227 (6.6%) | RR 0.45 (0.20 to 1.00) | 36 fewer per 1,000 (from 0 fewer to 53 fewer) | ⨁⨁⨁⨁ High | Important
PMID 31044749 · one of two readings recorded this
adverse events rate
no effect, p = 0.05
There was no significant difference in simethicone and water group (RR = 0.45, 95%CI: 0.2–1.0, P = 0.05, I2= 0%)
PMID 31044749 · one of two readings recorded this
positive findings event counts (GRADE profile)
no effect
3 | Randomized trials | Not serious | Serious* | Not serious | Not serious | None | 270/1879 (14.4%) | 235/1872 (12.6%) | RR 1.13 (0.82 to 1.55) | 16 more per 1,000 (from 23 fewer to 69 more) | ⨁⨁⨁◯ Moderate | Critical
PMID 31044749 · one of two readings recorded this
positive findings event counts (GRADE profile)
no effect
3 | Randomized trials | Not serious | Not serious | Not serious | Not serious | None | 252/717 (35.1%) | 265/783 (33.8%) | RR 1.02 (0.90 to 1.16) | 7 more per 1,000 (from 34 fewer to 54 more) | ⨁⨁⨁⨁ High | Critical
PMID 31044749 · one of two readings recorded this
positive findings rate
no effect, p = 0.46
There were no significant differences in the rate of positive findings comparing simethicone with water (RR = 1.13, 95%CI: 0.82–1.55, P = 0.46)
PMID 31044749 · one of two readings recorded this
positive findings rate
no effect, p = 0.71
Similar results were observed with simethicone plus NAC versus simethicone (RR = 1.02, 95%CI: 0.90-1.16, P = 0.71)
PMID 31044749 · one of two readings recorded this
procedure time
decreases, p = 0.00001
The procedure time in simethicone was shorter than that in water group (MD = −1.23 (−1.51, −0.96), P < 0.00001, I2= 31%)
PMID 31044749 · one of two readings recorded this
procedure time
no effect, p = 0.21
Compared with water, simethicone plus NAC showed no significant difference (MD = −0.81 (−2.06, −0.44), P = 0.21, I2= 0%)
PMID 31044749 · one of two readings recorded this
total mucosal visibility score at gastroscopy (four-point, three-point and other scales pooled), positive findings rate, procedure time and adverse events, simethicone plus NAC versus simethicone alone or water
MD = -0.14 (-0.25, -0.03) for simethicone plus NAC versus simethicone alone, p = 0.01
Not recorded as a finding: this platform holds no node for the endpoint
Simethicone plus NAC showed better TMVS than simethicone alone (MD = −0.14 (−0.25, −0.03), P = 0.01, I2= 0%) without significant heterogeneity.
PMID 31044749 · one of two readings recorded this
total mucosal visibility score at gastroscopy, simethicone plus NAC versus simethicone alone (simethicone given in both arms); also rate of positive findings and procedure time
MD = −0.14 (−0.25, −0.03), p = 0.01
Not recorded as a finding: this platform holds no node for the endpoint
Simethicone plus NAC showed better TMVS than simethicone alone (MD = −0.14 (−0.25, −0.03), P = 0.01, I2= 0%) without significant heterogeneity.
PMID 31044749 · one of two readings recorded this
total mucosal visibility score
modulates, p = 0.00001
Compared with water, simethicone displayed significant differences on TMVS with substantial heterogeneity (mean difference, MD = −3.62, (−4.65, −2.60), P < 0.00001, I2= 67%)
PMID 31044749 · one of two readings recorded this
total mucosal visibility score
modulates, p = 0.00001
Simethicone plus NAC showed similar effect than water (MD = −3.29 (−4.38, −2.21), P < 0.00001, I2= 60%)
PMID 31044749 · one of two readings recorded this
total mucosal visibility score
modulates, p = 0.0004
Removing the study by Asl et al. the heterogeneity reduced to low (I2= 28%), the meta-analysis result changed to: MD = −2.7 (−4.19, −1.22, P = 0.0004)
PMID 31044749 · one of two readings recorded this
hospital length of stay
no effect, p = 0.35, n = 1650
1,650 patients for hospital length of stay (HLoS) (MD -0.21 days, 95% CI -0.64 to 0.23; I2 = 89%; p = 0.35)
PMID 31071081 · one of two readings recorded this
intensive care unit length of stay
no effect, p = 0.73, n = 1512
1,512 patients for intensive care unit length of stay (ICULoS) (MD -0.04 days, 95% CI -0.29 to 0.20; I2 = 95%; p = 0.73)
PMID 31071081 · one of two readings recorded this
intensive care unit length of stay
decreases, p = 0.00001, n = 162
enriched cardioplegia solution with NAC compared to SoC in intensive care unit length of stay (MD -0.63 days, 95% CI -0.88 to -0.38; n = 162; I2 = 84%; p < 0.00001)
PMID 31071081 · one of two readings recorded this
acute myocardial infarction
no effect, p = 0.55, n = 1178
1,178 patients for acute myocardial infarction (RR 0.84, 95% CI 0.48 to 1.48; events (NAC:22/587, SoC:26/591); I2 = 0%; p = 0.55)
PMID 31071081 · one of two readings recorded this
acute renal insufficiency
no effect, p = 0.34, n = 1711
1,711 patients for acute renal insufficiency (RR 0.92, 95% CI 0.79 to 1.09; events (NAC:180/886, SoC:193/845); I2 = 0%; p = 0.34)
PMID 31071081 · one of two readings recorded this
arrhythmia
no effect, p = 0.27, n = 886
886 patients for arrhythmia (RR 0.79, 95% CI 0.52 to 1.20; events (NAC:81/446, SoC:98/440); I2 = 50%; p = 0.27)
PMID 31071081 · one of two readings recorded this
cardiac insufficiency
no effect, p = 0.38, n = 1149
1,149 patients for cardiac insufficiency (RR 0.77, 95% CI 0.44 to 1.38; events (NAC:19/572; SoC:24/577); I2 = 0%; p = 0.38)
PMID 31071081 · one of two readings recorded this
mortality, subgroups by route, dose, timing, technique and population
no effect
we found no statistically significant differences based on route, dose, timing of administration of NAC, surgical or anesthetic technique and characteristics of the population
PMID 31071081 · one of two readings recorded this
mortality
no effect, p = 0.23
mortality (RR 0.71, 95% CI 0.40 to 1.25; events (NAC:20/870, SoC:33/867); I2 = 0%; p = 0.23)
PMID 31071081 · one of two readings recorded this
acute exacerbation of COPD (AECOPD) risk
decreases
In the pairwise meta-analysis mucolytic/antioxidant agents significantly reduced the risk of AECOPD (RR 0.74 95%CI 0.68-0.80)
PMID 31133026 · one of two readings recorded this
duration of acute exacerbation of COPD (AECOPD), network meta-analysis of erdosteine, carbocysteine and NAC; also risk of AECOPD and hospitalization
decreases
Not recorded as a finding: this platform holds no node for the endpoint
Erdosteine and NAC both significantly reduced the duration of AECOPD (P < 0.01).
PMID 31133026 · one of two readings recorded this
duration of acute exacerbation of COPD (AECOPD), risk of AECOPD and hospitalization due to AECOPD, network meta-analysis of erdosteine, carbocysteine and NAC
decreases, significant reduction, P < 0.01 (no point estimate in the sentence)
Not recorded as a finding: this platform holds no node for the endpoint
Erdosteine and NAC both significantly reduced the duration of AECOPD (P < 0.01).
PMID 31133026 · one of two readings recorded this
duration of AECOPD
decreases, p = 0.01
Erdosteine and NAC both significantly reduced the duration of AECOPD (P < 0.01)
PMID 31133026 · one of two readings recorded this
duration of AECOPD
decreases, p = 0.01
Erdosteine and NAC both significantly reduced the duration of AECOPD (P < 0.01)
PMID 31133026 · one of two readings recorded this
hospitalization due to AECOPD
decreases, p = 0.05
Only erdosteine reduced the risk of experiencing at least one AECOPD (P < 0.01) and the risk of hospitalization due to AECOPD (P < 0.05)
PMID 31133026 · one of two readings recorded this
risk of at least one AECOPD
decreases, p = 0.01
Only erdosteine reduced the risk of experiencing at least one AECOPD (P < 0.01) and the risk of hospitalization due to AECOPD (P < 0.05)
PMID 31133026 · one of two readings recorded this
Progression-free survival
increases, p = 0.016
PFD + NAC treatment showed favourable results regarding the PFS (median survival days 304 d vs 168 d; p = 0.016)
PMID 32380989 · one of two readings recorded this
At least one side effect
no effect, p = 0.314
similar (PFD + NAC vs PFD alone: 41 vs 57, OR = 1.83, 95% CI 0.56–5.94, p = 0.314, Fig. 3a)
PMID 32380989 · one of two readings recorded this
At least one side effect
no effect, p = 0.592
SE | 0.56–5.94 | 0.314 | 0.43–5.17 | 0.068 | 0.33–1.88 | 0.592
PMID 32380989 · one of two readings recorded this
At least one side effect
no effect, p = 0.068
SE | 0.56–5.94 | 0.314 | 0.43–5.17 | 0.068 | 0.33–1.88 | 0.592
PMID 32380989 · one of two readings recorded this
Change in 6MWD
no effect, p = 0.54
between the observational study (− 13.25 ± 6.77 vs − 16.59 ± 4.65, p = 0.159) and Behr’s RCT (− 4.3 vs − 11.7, p = 0.54)
PMID 32380989 · one of two readings recorded this
Change in 6MWD
no effect, p = 0.159
between the observational study (− 13.25 ± 6.77 vs − 16.59 ± 4.65, p = 0.159) and Behr’s RCT (− 4.3 vs − 11.7, p = 0.54)
PMID 32380989 · one of two readings recorded this
Change in DLco% predicted from baseline to week 24
no effect, p = 0.58
There was no difference in the ΔDLco% between the PFD + NAC group and the PFD group (SMD = 0.13, 95% CI -0.34-0.61, p = 0.580, Fig. 2b)
PMID 32380989 · one of two readings recorded this
Change in DLco% predicted
no effect, p = 0.73
ΔDLco% | −0.34-0.62 | 0.580 | NA | NA | −2.44-2.22 | 0.730
PMID 32380989 · one of two readings recorded this
Change in FVC% predicted from baseline to week 24
no effect, p = 0.295
PFD + NAC therapy had no additional benefit in reducing the decrease in lung function (SMD = -0.09, 95% CI − 0.86-0.69, p = 0.295, Fig. 2a)
PMID 32380989 · one of two readings recorded this
Change in FVC% predicted
no effect, p = 0.2
ΔFVC% | -0.86-0.69 | 0.693 | NA | NA | −4.23-0.13 | 0.200
PMID 32380989 · one of two readings recorded this
change in predicted DLco% from baseline to week 24, pooled standardised mean difference
no effect, SMD 0.13; 95% CI -0.34 to 0.61, p = 0.58
Not recorded as a finding: no outcome node for diffusing capacity for carbon monoxide
There was no difference in the ΔDLco% between the PFD + NAC group and the PFD group (SMD = 0.13, 95% CI -0.34-0.61, p = 0.580, Fig. 2b).
PMID 32380989 · one of two readings recorded this
change in predicted FVC% from baseline to week 24, pooled standardised mean difference
no effect, SMD -0.09; 95% CI -0.86 to 0.69, p = 0.295
Not recorded as a finding: no outcome node for forced vital capacity percent predicted
The results showed that PFD + NAC therapy had no additional benefit in reducing the decrease in lung function (SMD = -0.09, 95% CI − 0.86-0.69, p = 0.295, Fig. 2a) compared to PFD alone.
PMID 32380989 · one of two readings recorded this
change in predicted FVC (ΔFVC%) and predicted DLco (ΔDLco%) from baseline to week 24, PFD + NAC versus PFD alone, pooled SMD
SMD = -0.09, 95% CI − 0.86-0.69, p = 0.295
Not recorded as a finding: this platform holds no node for the endpoint
The results showed that PFD + NAC therapy had no additional benefit in reducing the decrease in lung function (SMD = -0.09, 95% CI − 0.86-0.69, p = 0.295, Fig. 2a) compared to PFD alone.
PMID 32380989 · one of two readings recorded this
Gastrointestinal side effects
no effect, p = 0.811
gastrointestinal (GI): 26 vs 47, I2 = 30.9%, p = 0.215, OR = 1.08, 95% CI 0.56–2.08, p = 0.811, Fig. 4a
PMID 32380989 · one of two readings recorded this
Gastrointestinal side effects
no effect, p = 0.475
GI_SE | 0.56–2.08 | 0.811 | 0.46–1.83 | 0.249 | 0.33–1.68 | 0.475
PMID 32380989 · one of two readings recorded this
Gastrointestinal side effects
no effect, p = 0.249
GI_SE | 0.56–2.08 | 0.811 | 0.46–1.83 | 0.249 | 0.33–1.68 | 0.475
PMID 32380989 · one of two readings recorded this
intolerable side effects leading to treatment discontinuation, pooled odds ratio
no effect
Not recorded as a finding: the quoted sentence says intolerable side effects were at a similar frequency but never states discontinuation, so the withdrawal-due-to-adverse-events node is not self-evidently matched
Patients receiving PFD + NAC therapy experienced intolerable side effects at a similar frequency as in those receiving PFD alone.
PMID 32380989 · one of two readings recorded this
Intolerable side effects leading to treatment discontinuation
no effect, p = 0.092, n = 100
combined PFD + NAC therapy did not increase the risk of intolerable side effects (OR = 2.85, 95% CI 0.84–9.59, p = 0.092, Fig. 3b)
PMID 32380989 · one of two readings recorded this
Intolerable side effects leading to treatment discontinuation
no effect, p = 0.635
Intole_SE | 0.84–9.59 | 0.092 | 0.52–8.32 | 0.955 | 0.31–6.78 | 0.635
PMID 32380989 · one of two readings recorded this
Intolerable side effects leading to treatment discontinuation
no effect, p = 0.955
Intole_SE | 0.84–9.59 | 0.092 | 0.52–8.32 | 0.955 | 0.31–6.78 | 0.635
PMID 32380989 · one of two readings recorded this
Skin side effects
no effect, p = 0.162
skin side effects: 12 vs 17, I2 = 0%, p = 0.769, OR = 1.91, 95% CI 0.77–4.71, p = 0.162, Fig. 4b
PMID 32380989 · one of two readings recorded this
Skin side effects
increases, p = 0.038
Skin_SE | 0.77–4.71 | 0.162 | 0.74–4.88 | 0.611 | 1.14–77.52 | 0.038
PMID 32380989 · one of two readings recorded this
Skin side effects
no effect, p = 0.611
Skin_SE | 0.77–4.71 | 0.162 | 0.74–4.88 | 0.611 | 1.14–77.52 | 0.038
PMID 32380989 · one of two readings recorded this
All-cause in-hospital mortality
decreases, p = 0.01
all-cause in-hospital mortality by 63% (RR 0.37, 95% CI 0.17 to 0.79, p=0.01)
PMID 33067289 · one of two readings recorded this
Contrast-associated acute kidney injury
decreases, p = 0.01, n = 1710
significantly reduced the incidence of CA-AKI by 49% (risk ratio (RR) 0.51, 95% CI 0.31 to 0.82, p<0.01)
PMID 33067289 · one of two readings recorded this
requirement for dialysis after contrast exposure, pooled risk ratio
no effect, RR 0.61; 95% CI 0.11 to 3.38, p = 0.24
Not recorded as a finding: no outcome node for requirement for dialysis / renal replacement
The estimated effects on the requirement for dialysis (RR 0.61, 95% CI 0.11 to 3.38, p=0.24) were not statistically significant.
PMID 33067289 · one of two readings recorded this
requirement for dialysis, pooled risk ratio
no effect, RR 0.61, 95% CI 0.11 to 3.38, p = 0.24
Not recorded as a finding: no outcome node for dialysis requirement
The estimated effects on the requirement for dialysis (RR 0.61, 95% CI 0.11 to 3.38, p=0.24) were not statistically significant.
PMID 33067289 · one of two readings recorded this
Requirement for dialysis
no effect, p = 0.24
The estimated effects on the requirement for dialysis (RR 0.61, 95% CI 0.11 to 3.38, p=0.24)
PMID 33067289 · one of two readings recorded this
Acute kidney injury after cardiac surgery
no effect, n = 1242
Overall results showed that the effect of NAC in preventing AKI after adult cardiac surgery was equivocal, as shown in Fig. 2 (OR: 0.84, 95% CI: 0.64–1.10)
PMID 34732600 · one of two readings recorded this
Acute kidney injury after cardiac surgery
no effect
This is shown in Fig. 5 (OR: 1.01, 95% CI: 0.73–1.41) and Supplemental Fig. 1 (OR: 0.66, 95% CI: 0.32–1.36), respectively
PMID 34732600 · one of two readings recorded this
Acute kidney injury after cardiac surgery
no effect
This is shown in Fig. 5 (OR: 1.01, 95% CI: 0.73–1.41) and Supplemental Fig. 1 (OR: 0.66, 95% CI: 0.32–1.36), respectively
PMID 34732600 · one of two readings recorded this
Acute kidney injury after cardiac surgery
no effect
as shown in Fig. 3 (OR: 0.77, 95% CI: 0.56–1.07) and Fig. 4 (OR: 1.10, 95% CI: 0.64–1.89), respectively
PMID 34732600 · one of two readings recorded this
Acute kidney injury after cardiac surgery
no effect
as shown in Fig. 3 (OR: 0.77, 95% CI: 0.56–1.07) and Fig. 4 (OR: 1.10, 95% CI: 0.64–1.89), respectively
PMID 34732600 · one of two readings recorded this
acute kidney injury incidence after cardiac surgery, pooled OR across 10 trials with differing AKI definitions (creatinine rise or AKIN)
OR: 0.84, 95% CI: 0.64–1.10
Not recorded as a finding: primary outcome. Overall sentence says the effect was equivocal and the next sentence omits the AKI object; no two-sided statement with the compound and endpoint in one sentence
Overall results showed that the effect of NAC in preventing AKI after adult cardiac surgery was equivocal, as shown in Fig. 2 (OR: 0.84, 95% CI: 0.64–1.10).
PMID 34732600 · one of two readings recorded this
In-hospital mortality
no effect, n = 1055
Meta-analytic estimates for in-hospital mortality showed that there was no statistically significant difference between patients treated with NAC and without, as shown in Supplemental Fig. 6 (OR: 0.85, 95% CI: 0.43–1.68)
PMID 34732600 · one of two readings recorded this